Floatz logo

Lapatinib

HER-2 Gene Amplification

Merrimack PharmaceuticalsSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the HER-2 Gene Amplification cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
Jin-Hee Ahn
Phase 2B
Pyrotinib
Tianjin Medical University Second Hospital
Phase 2CCC
her2 dc1 vaccine
H. Lee Moffitt Cancer Center and Research Institute
Phase 2CCC
Irinotecan
Jin-Hee Ahn
Phase 2CCC
ANTI-HER2 ANTIBODY-DRUG CONJUGATE A166
Klus Pharma Inc.
Phase 1/2CCC

View all 14 →

Same molecule, other indications

Lapatinib is also rated in:

breast cancerDormant
BBB
Indicative ·
76 / 100
View asset →
breast carcinomaDormant
BB
Indicative ·
67 / 100
View asset →
male breast carcinomaDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →